Back to Search
Start Over
Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
- Source :
-
Biology of Blood & Marrow Transplantation . Sep2018, Vol. 24 Issue 9, p1828-1835. 8p. - Publication Year :
- 2018
-
Abstract
- Highlights • Semiablative melphalan-based conditioning regimen is safe for eligible elderly patients. • Rapid hematopoietic reconstitution after this regimen led to favorable survival outcomes. • Morbidity indicators (infection, etc.) were similar to younger patients undergoing same regimen. • This regimen is effective with promising relapse rate and minimal toxicities for patients > 70. Abstract Allogeneic hematopoietic stem cell transplantation (alloHCT) is offered increasingly to elderly patients with hematologic malignancies. However, outcome data in those who are 70 years or older are limited, and no standard conditioning regimen has been established for this population. In this retrospective study we evaluated the outcome of 53 consecutive patients aged 70 years and older who underwent alloHCT with melphalan-based reduced-intensity conditioning (RIC) at City of Hope. Engraftment was prompt, with median time to neutrophil engraftment of 15 days. More than 95% of patients achieved complete donor chimerism within 6 weeks from HCT, consistent with the "semiablative" nature of this regimen. With a median follow-up of 31.1 months, the 2-year overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM) were 68.9%, 63.8%, and 17.0%, respectively. Cumulative incidence of relapse at 1 and 2 years was 17.0% and 19.3%, respectively. One hundred–day cumulative incidence of grades II to IV acute graft-versus-host disease was 37.7% (grades III to IV, 18.9%), and 2-year cumulative incidence of chronic graft-versus-host disease was 61.9% (extensive, 45.9%). The only significant predictor for poor OS was high/very high disease risk index. Transplant-related complications and morbidities observed here did not differ from the commonly expected in younger patients treated with RIC. In conclusion, alloHCT with a melphalan-based conditioning regimen is associated with acceptable toxicities and NRM, lower incidence of relapse, and favorable OS and PFS in patients aged 70 years or older. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10838791
- Volume :
- 24
- Issue :
- 9
- Database :
- Academic Search Index
- Journal :
- Biology of Blood & Marrow Transplantation
- Publication Type :
- Academic Journal
- Accession number :
- 131946920
- Full Text :
- https://doi.org/10.1016/j.bbmt.2018.04.029